Welcome to our dedicated page for Amyris news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on Amyris stock.
Amyris, Inc. (Nasdaq: AMRS) is a pioneering synthetic biotechnology company that leverages its Lab-to-Market™ technology platform to facilitate the world's shift towards sustainable consumption. Founded with the vision of transforming the Clean Health & Beauty and Flavors & Fragrances markets, Amyris specializes in converting plant sugars into essential hydrocarbon molecules, specialty ingredients, and consumer products using innovative bioscience solutions. The company's proprietary technology platform utilizes advanced machine learning, robotics, and artificial intelligence to bring new innovations to market at commercial scale, resulting in products incorporated into over 20,000 items from leading global brands, impacting more than 300 million consumers.
Recently, Amyris has undergone significant changes to optimize its operations and financial health. In June 2023, the company announced the resignation of its President & CEO, John Melo, with Han Kieftenbeld stepping in as Interim CEO while continuing his role as CFO. This leadership change aligns with Amyris' broader strategy to streamline its business and achieve cost reduction targets, including a global reduction in force and collaboration with PricewaterhouseCoopers (PwC) to implement 'Fit-to-Win' cost actions estimated at $250 million.
Further advancing its strategic transformation, Amyris commenced voluntary Chapter 11 proceedings in August 2023 to restructure its operations and financial framework. This restructuring aims to enhance the company's cost structure, capital position, and liquidity, allowing it to refocus on its core competencies in research and development, commercialization, and the application of sustainable ingredients through biofermentation. As part of this effort, Amyris plans to exit from its consumer brands, marketing them for sale while continuing to operate them through retail and e-commerce platforms during the transition.
Amyris has secured $190 million in debtor-in-possession financing from Foris Ventures to support its daily operations and meet its commitments to employees, customers, and partners throughout the restructuring process. The company is committed to maintaining its innovative edge and remains dedicated to introducing sustainable, effective, and accessible products to market, ensuring a path toward profitable growth and sustained cash generation.
More information about Amyris and its ongoing projects and initiatives can be found on their official website, www.amyris.com.
Amyris, Inc. (Nasdaq: AMRS) announced a partnership between its Pipette brand and Baby2Baby to donate 200,000 hand sanitizers to impoverished families nationwide. This initiative supports Pipette's 'Healthy Hands' mission, providing clean and effective solutions to safeguard children amid the COVID-19 pandemic. Since its launch in March 2020, Pipette's hand sanitizer has gained recognition for containing 65% ethyl alcohol, effectively eliminating 99.99% of germs. The collaboration aims to enhance health and hygiene for vulnerable populations, reflecting Amyris's commitment to social responsibility.
Amyris, Inc. (Nasdaq: AMRS) has signed a $100 million agreement with Ingredion Incorporated (NYSE: INGR) to exclusively license its zero-calorie fermented Reb M sweetener. The deal includes Ingredion acquiring a minority stake in Amyris's Brazilian manufacturing facility currently under construction. This collaboration aims to accelerate the production and marketing of sustainable sweeteners and fermentation-based ingredients. The transaction, expected to close in the second quarter, positions both companies to enhance their offerings in the food and beverage industry through sustainable solutions.
Amyris, Inc. (Nasdaq: AMRS) successfully concluded its third webinar in the "Delivering on the Promise of Synthetic Biology" series on April 22, 2021. The event streamed live with over 350 investors participating, featuring leaders including CEO John Melo and guest speaker Fernando Galletti De Queiroz from Minerva Foods. The presentation focused on Amyris's commitment to sustainability, its Lab-to-Market capabilities, and the company's innovative technology that enhances supply chains and sustainably sourced ingredients. The company aims to revolutionize the Clean Health and Beauty markets.
Amyris, Inc. (Nasdaq: AMRS) will announce its financial results for the first quarter ending March 31, 2021, on May 6, 2021, before market opening. The company will host a conference call at 6:00 AM PT (9:00 AM ET) to discuss these results and provide an update on its business. Key executives, including CEO John Melo and CFO Han Kieftenbeld, will be present. Amyris specializes in sustainable ingredients for Clean Health and Beauty markets, leveraging advanced technologies such as AI and machine learning.
Amyris, Inc. (Nasdaq: AMRS) announced the acquisition of EcoFabulous Cosmetics, a brand targeting the Gen Z beauty market. This acquisition aims to enhance Amyris's position in the clean beauty segment, leveraging EcoFabulous's focus on sustainable ingredients. The deal grants Amyris a 70% controlling interest, with plans for significant growth through innovative offerings and direct-to-consumer strategies. Amyris has invested approximately $12 million in new brand acquisitions, anticipating these brands to contribute 20% to consumer revenue this year.
Amyris, Inc. (Nasdaq: AMRS) has announced its acquisition of Beauty Labs International Ltd., an AI technology leader that enhances consumer experiences in beauty and wellness. This strategic move aims to accelerate Amyris's growth in clean beauty, leveraging Beauty Labs' innovative AI technology to create personalized consumer experiences across its brands like Biossance and Pipette. With a cash balance of $250 million and a strong ingredients pipeline, Amyris expects the deal to enhance its e-commerce revenue and deepen connections with consumers. The transaction is expected to close within 30 days, pending due diligence.
Amyris, a synthetic biotechnology company, announced a public offering of 19,047,619 shares of common stock at $15.75 per share, raising approximately $120.6 million for the company. The offering consists of a secondary sale of 11,390,797 shares by DSM International and Vivo Capital, with Amyris selling 7,656,822 shares. The underwriters have a 30-day option to purchase an additional 2,857,142 shares. The offering is set to close on or around April 13, 2021, subject to customary conditions.
Amyris, Inc. (Nasdaq: AMRS) announced a proposed underwritten public offering of common stock amounting to $100 million to bolster its growth, while $150 million will be offered by current stockholders DSM International B.V. and Vivo Capital LLC. The offering includes a potential additional $37.5 million option for underwriters. Amyris will not benefit financially from the stockholder sale. The offering is subject to market conditions and is governed by an automatic shelf registration with the SEC.
Amyris, Inc. (Nasdaq: AMRS) has announced a 5-year partnership with Reese Witherspoon as the global brand ambassador for Biossance®, a rapidly growing clean skincare brand. This collaboration aims to enhance consumer awareness and education surrounding clean beauty. Witherspoon will create engaging content and limited-edition products, focusing on sustainability and skincare efficacy. Biossance emphasizes a commitment to high-performance, clean ingredients and is recognized for its leadership in the clean beauty movement. This partnership is expected to drive growth and consumer engagement in the sustainable skincare market.
Amyris (Nasdaq: AMRS) announced participation in the Cowen's 2nd Annual Consumer Platforms for the Next Generation Summit on April 6, 2021, at 9:30 am ET. The event will include a fireside chat to discuss the company's advancements in synthetic biotechnology for the Clean Health and Beauty markets. A live webcast and replay will be available on their Investor Relations website. Amyris is a leader in sustainable ingredients, serving over 200 million consumers through its brands like Biossance and Pipette.
FAQ
What does Amyris, Inc. specialize in?
What is the Lab-to-Market™ technology platform?
Who is the current CEO of Amyris?
What recent strategic changes has Amyris implemented?
How is Amyris supporting its operations during the restructuring?
What is Amyris' 'Fit-to-Win' initiative?
Will Amyris continue to operate its consumer brands?
What is the impact of Amyris' products on the market?
How can stakeholders get more information about Amyris' restructuring?
Where can I find more information about Amyris?
